

Patent Attorney Docket No. 81640 Customer No. 23685

TC 170

## TRANSMITTAL LETTER

Inventor: Oliver Danne et al.

Serial No: 09/762,691 Filed: February 9, 2001 Examiner: Monique T. Cole Group Art Unit: 1743

Confirmation No:

For: IN-VITRO METHOD FOR DETECTING AND DIAGNOSING ACUTE CORONARY

**SYNDROMES** 

Mail Stop Fee Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith for the above-identified patent application are the following:

A Supplemental Information Disclosure Statement Form PTO-FB-A820 (5 sheets) Copies of 12 documents A check for \$180 A postcard

The item(s) checked below are appropriate:

1. \_\_ Applicant(s) hereby petition(s) for a () month extension of time to respond to

2. Please charge any fees or costs not accounted for to Deposit Account No. 11-

1755.

3. ✓ Applicant is a small entity.

Date: November 13, 2003

Edward M/Kriegsman

Reg. No./33,529

KRIEGSMAN & KRIEGSMAN 665 Franklin Street Framingham, MA 01702 (508) 879-3500

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on <u>November 13</u>, 2003

Edward M. Kriegsman



#19

PATENT Attorney Docket No. 81640 Customer No. 23685

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
OLIVER DANNE ET AL.	)
Serial No.: 09/762,691	) Group Art Unit: 1743
Filed: February 9, 2001	Examiner: Monique T. Cole
For: IN-VITRO METHOD FOR DETECTING AND DIAGNOSING ACUTE CORONARY SYNDROMES	Ooling the state of the state o
Mail Stop Fee Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	ESTOCIALIZA
Sir	

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, Applicants disclose the following information:

- 1. Wu et al., "Ischemia-Modified Albumin, Free Fatty Acids, Whole Blood Choline, B-Type Natriuretic Peptide, Glycogen Phosphorylase BB, and Cardiac Troponin," <u>Cardiac Markers</u>, Second Edition, edited by Alan H.B. Wu, Humana Press, Totowa, NJ (2003);
- 2. Abstract by Danne et al. entitled "Whole Blood Choline and Plasma Choline Concentration for Early Risk-Stratification of Troponin I-negative Acute Coronary Syndromes," published November 9-12, 2003, at Scientific Sessions 2003 conference in Orlando, Florida;
- 3. Danne et al., "Prognostic Implications of Elevated Whole Blood Choline Levels in Acute Coronary Syndromes," <u>Am. J. Cardiol.</u>, 91:1060-7 (May 1, 2003);
- 4. The Joint European Society of Cardiology/American College of Cardiology Committee, "Myocardial Infarction Redefined-A Consensus Document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction," Journal of the American College of Cardiology, 36(3):959-69 (2000);

11/19/2003 NROCHA1 00000015 09762691

- 5. Chierchia, "Current therapeutic strategies in unstable angina," <u>European Heart Journal Supplements</u>, 1(Supplement N):N2-N6 (1999);
- 6. Ryan et al., "ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction," <u>JACC</u>, 28(5):1328-428 (1996);
- 7. Ohman et al., "Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia," The New England Journal of Medicine, 335(18):1333-41 (1996);
- 8. Van Miltenburg-van Zijl et al., "Incidence and Follow-Up of Braunwald Subgroups in Unstable Angina Pectoris," <u>JACC</u>, 25(6):1286-92 (1995);
- 9. Groenendaal et al., "Proton Magnetic Resonance Spectroscopic Imaging in Neonatal Stroke," Neuropediatrics, 26:243-8 (1995);
- 10. "Unstable Angina: Diagnosis and Management," Clinical Practice Guideline Number 10, AHCPR Publication No. 94-0602: May 1994 (amended);
- 11. Braunwald et al., "Diagnosing and Managing Unstable Angina," <u>Circulation</u>, 90(1):613-22 (1994); and
- 12. Corr et al., "Lysophosphoglycerides and Ventricular Fibrillation Early After Onset of Ischemia," J. Mol. Cell. Cardiol., 19(Supplement V):45-53 (1987).

Copies of the foregoing documents are provided with this paper. In addition, these documents are listed on the enclosed PTO Form FB-A820. Applicants respectfully request that the Examiner consider the enclosed documents and evidence that consideration by making appropriate notations on the enclosed form.

This submission does not represent that a search has been made or that no better prior art exists and does not constitute an admission that the enclosed documents constitute "prior art."

Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the enclosed documents, should the documents be applied against the claims of the present invention.

A check in the amount of \$180.00 is enclosed herewith in accordance with the provisions of 37 C.F.R. 1.17(p). If there are any other fees due in connection with the filing of this paper that are not accounted for, the Examiner is authorized to charge the fees to our Deposit Account No. 11-1755. If a fee is required for an extension of time under 37 C.F.R. 1.136 that is not accounted for

already, such an extension of time is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

Kriegsman & Kriegsman

Edward M. Kriegsman

665 Frankfin Street

Framingham, MA 01702

(508) 879-3500

Dated: November 13, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 13 2003

Reg. No. 33,529 Dated: November 6, 2003